 | • レポートコード：TPM-NV148 • 出版社/出版日：Transparency Market Research / 2019年11月8日 • レポート形態：英文、PDF、167ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、咳過敏症候群治療の世界市場について調べ、咳過敏症候群治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別（鎮咳薬、吸入コルチコステロイド、短時間作用型ベータ2アゴニスト、抗コリン薬、抗ヒスタミン薬、プロトンポンプ阻害薬、その他）分析、流通チャンネル別（病院薬局、小売薬局、オンライン薬局）分析、関連企業情報などをまとめました。 ・咳過敏症候群治療の市場概要 ・咳過敏症候群治療の市場動向 ・咳過敏症候群治療の世界市場規模・予測 ・咳過敏症候群治療市場：薬物クラス別（鎮咳薬、吸入コルチコステロイド、短時間作用型ベータ2アゴニスト、抗コリン薬、抗ヒスタミン薬、プロトンポンプ阻害薬、その他） ・咳過敏症候群治療市場：流通チャンネル別（病院薬局、小売薬局、オンライン薬局） ・地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争環境・関連企業分析 |
On a global level, the alarming prevalence of chronic cough amongst individuals has propelled healthcare companies in the cough hypersensitivity syndrome treatment market to develop efficacious treatment options. As such, they are increasing their focus on developing improved formulations of antitussive agents. This trend is distinctly true, since antitussive agents are projected to dominate the cough hypersensitivity syndrome treatment market, with an estimated revenue of ~US$ 2.8 billion by 2027.
In order to relieve patients from cough hypersensitivity, healthcare companies are investing in opiates and GABA (gamma-aminobutyric acid)-related compounds. Opiates serve as effective cough suppressants and possess efficacious antitussive properties to treat chronic intractable cough. Likewise, companies are increasing their production capabilities of tramadol, an opioid medication that is similar to the molecular formula of codeine drugs.
Since chronic cough causes increased body pain, companies in the cough hypersensitivity syndrome treatment market are increasing the availability of babapentin and pregabalin, which are GABA-related compounds, and act as neuromodulators for the treatment of neuropathic pain and epilepsy. It has been found in placebo-controlled trials that, gabapentin is well-tolerated for the treatment of refractory chronic cough.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Cough Hypersensitivity Syndrome Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Respiratory Drug Classes Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Epidemiology Cough hypersensitivity syndrome
5.2. Pipeline Analysis
6. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Drug Class, 2017–2027
6.3.1. Antitussive Agents
6.3.2. Inhaled Corticosteroids (ICS)
6.3.3. Short Acting Beta2-Agonists (SABA)
6.3.4. Anti-cholinergics
6.3.5. Antihistamines
6.3.6. Proton Pump Inhibitors
6.3.7. Others
6.4. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Drug Class
7. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel
8. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Region
8.1. Key Findings
8.2. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Region
9. North America Cough Hypersensitivity Syndrome Treatment Market Value Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
9.2.1. Antitussive Agents
9.2.2. Inhaled Corticosteroids (ICS)
9.2.3. Short Acting Beta2-Agonists (SABA)
9.2.4. Anti-cholinergics
9.2.5. Antihistamines
9.2.6. Proton Pump Inhibitors
9.2.7. Others
9.3. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
10.2.1. Antitussive Agents
10.2.2. Inhaled corticosteroids (ICS)
10.2.3. Short-Acting Beta2-Agonists (SABA)
10.2.4. Anti-cholinergics
10.2.5. Antihistamines
10.2.6. Proton Pump Inhibitors
10.2.7. Others
10.3. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country
11. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
11.2.1. Antitussive Agents
11.2.2. Inhaled corticosteroids (ICS)
11.2.3. Short-Acting Beta2-Agonists (SABA)
11.2.4. Anti-cholinergics
11.2.5. Antihistamines
11.2.6. Proton Pump Inhibitors
11.2.7. Others
11.3. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
12.2.1. Antitussive Agents
12.2.2. Inhaled corticosteroids (ICS)
12.2.3. Short-Acting Beta2-Agonists (SABA)
12.2.4. Anti-cholinergics
12.2.5. Antihistamines
12.2.6. Proton Pump Inhibitors
12.2.7. Others
12.3. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
13.2.1. Antitussive Agents
13.2.2. Inhaled corticosteroids (ICS)
13.2.3. Short-Acting Beta2-Agonists (SABA)
13.2.4. Anti-cholinergics
13.2.5. Antihistamines
13.2.6. Proton Pump Inhibitors
13.2.7. Others
13.3. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027
13.4.1. GCC
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis by Company (2018)
14.3. Company Profiles
14.3.1. Pfizer, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. Strategic Overview
14.3.1.5. SWOT Analysis
14.3.2. GlaxoSmithKline plc
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. Strategic Overview
14.3.2.5. SWOT Analysis
14.3.3. Boehringer Ingelheim GmbH
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. Strategic Overview
14.3.3.5. SWOT Analysis
14.3.4. AstraZeneca
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. Strategic Overview
14.3.4.5. SWOT Analysis
14.3.5. F. Hoffmann-La Roche Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. Strategic Overview
14.3.5.5. SWOT Analysis
14.3.6. Teva Pharmaceutical Industries Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. Strategic Overview
14.3.6.5. SWOT Analysis
14.3.7. Novartis AG
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. Strategic Overview
14.3.7.5. SWOT Analysis
14.3.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp)
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. Strategic Overview
14.3.8.5. SWOT Analysis
14.3.9. Vertex Pharmaceuticals Incorporated
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. Strategic Overview
14.3.9.5. SWOT Analysis
14.3.10. Johnson & Johnson Consumer Inc.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. Strategic Overview
14.3.10.5. SWOT Analysis